By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Analgesic combinations > Bupivacaine and meloxicam > Bupivacaine and meloxicam Pregnancy and Breastfeeding Warnings
Analgesic combinations

Bupivacaine / meloxicam Pregnancy and Breastfeeding Warnings

Contents
Bupivacaine and meloxicam Pregnancy Warnings Bupivacaine and meloxicam Breastfeeding Warnings

Bupivacaine and meloxicam Pregnancy Warnings

Animal studies are not available for the combination product. There are no controlled data in human pregnancy.

Bupivacaine:
Animal studies of subcutaneous administration during organogenesis, at doses comparable to the maximum recommended human dose (MRHD) showed no embryofetal effects in the high dose which caused increased maternal lethality in rats, and increased embryofetal deaths at the high dose in the absence of maternal toxicity in rabbits; the fetal No Observed Adverse Effect Level was approximately 0.3 times the MRHD.

Meloxicam:
Animal data: Animal studies of oral administration of meloxicam during organogenesis at doses 3 times the 12 mg meloxicam dose showed no embryofetal malformations in rats. In rabbits, administration throughout embryogenesis produced increased incidence of septal defects of the heart at 97 times the MRHD; the No Effect Level was 32 times the MRHD. Oral administration to rats from late gestation through lactation showed increased dystocia incidence, delayed parturition, and decreased offspring survival at dose 0.1 times the MRHD or greater.

Fertility:
Prostaglandin-mediated NSAIDs, including meloxicam, may delay or rupture ovarian follicles, which is associated with reversible infertility in some patients. Animal studies showed prostaglandin synthesis inhibitors have the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small human studies showed a reversible delay in ovulation with NSAID use. An animal study of oral meloxicam for 35 days showed decreased sperm count and motility, and histopathological evidence of testicular degeneration at 0.8 times the MRHD; it is not known if these effects are reversible.


US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Avoid use at about 30 weeks gestation and later.

US FDA pregnancy category: Not assigned

Risk summary: Use of NSAIDs at about 30 weeks gestation and later may produce premature closure of the fetal ductus arteriosus; use of NSAIDs at about 20 weeks gestation and later is associated with fetal renal dysfunction leading to oligohydramnios and potentially neonatal renal impairment.

Comments:
-There is no data on use in pregnant women to know this drugs risks, including the risk of fetal harm or reproductive effects.
-Fetal renal dysfunction leading to oligohydramnios and potentially neonatal renal impairment is typically seen after days to weeks of NSAID treatment, but has infrequently occurred as soon as 48 hours after NSAID initiation.
-Oligohydramnios is often, but not always, reversible with drug discontinuation.
-Prolonged oligohydramnios may lead to complications such as limb contractures and delayed lung maturation.
-Some postmarketing cases of impaired neonatal renal functions have required invasive procedures such as exchange transfusion or dialysis.
-Limitations of postmarketing reports and studies includes lack of a control group, limited information on dose, duration, and timing of exposure, and use of other medications. Data on outcomes mostly involved preterm infants, making generalizability of the risks to a full-term infant uncertain.
-If NSAID treatment is needed between 20- and 30-weeks gestation, use the lowest effective dose and consider ultrasound monitoring for oligohydramnios.
-Treat oligohydramnios according to clinical practice.
-Animal studies of NSAIDs, including meloxicam, showed inhibited prostaglandin synthesis, delayed parturition, and increased stillbirth incidence.

See references

Bupivacaine and meloxicam Breastfeeding Warnings

The manufacturer makes no recommendation regarding use during lactation.

Excreted into human milk: Yes (bupivacaine)/Data not available (meloxicam)
Excreted into animal milk: Yes (meloxicam)

Comments:
-There is no information regarding this drug on the effects on a breastfed infant, or effects on milk production.
-Limited literature reports low levels of bupivacaine and its primary metabolite, pipecoloxylidine (PXX) in human milk.
-Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for this medication as well as any potential adverse effects from this drug or the underlying maternal condition.

-After administration of this product to lactating animals, bupivacaine and meloxicam were detected in the milk, but only bupivacaine was detected in the plasma of the suckling offspring.
-Meloxicam was present in rat milk at concentrations higher than those in plasma.

See references

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by